Trial Profile
A study evaluating efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jun 2017
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 16 May 2017 New trial record